JPRN-UMIN000012048已完成2 期
Phase II study of low-dose Nab-paclitaxel for advanced breast cancer - Phase II study of low-dose Nab-paclitaxel for advanced breast cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) History of hypersensitivity reaction 2) Active double cancer 3) Other severe complications, such as uncontrolled diabetes mellitus, uncontrolled angina, myocardial infarction within 6 months, heart failure. 4) Severe mental disorder 5) Sever bone marrow suppression, renal dysfunction, liver dysfunction 6) Has watery diarrhea 7) Active infection or potentiality infection 8) History of hypersensitivity for albumin 9) Grade2 or grater peripheral neuropathy 10) Pregnant or lactating women, women who are capable of pregnancy, intend to get pregnant 11) Judged ineligible based on physicians' decision
研究者
相似试验
尚未招募
2 期
A phase II study of low dose nab-paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancerunresectable or recurrent gastric canceJPRN-UMIN000016196Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine37
招募中
2 期
Phase 2 study of dose-dense nab-paclitaxel followed by EC as neoadjuvant chemotherapy for HER2-negative breast cancerHER2-negative primary breast cancerJPRN-UMIN000026143Teikyo University School of Medicine50
已完成
不适用
A phase II study of nab-paclitaxel for pretreated non-small cell lung canceron-small cell lung cancerJPRN-UMIN000012972Kanagawa Cancer Center30
已完成
2 期
A phase 2 trial of weekly nab-paclitaxel for advanced non-small cell lung cancer without EGFR mutation nor ALK fusion gene in salvage settingJPRN-UMIN000016173Kurashiki Central Hospital38
已完成
2 期
Phase II clinical study of nab-paclitaxel for patients with recurrent advanced non-small cell lung cancer.advanced non-small cell lung cancerJPRN-UMIN000016932The Japan-Multinational Trial Organization (JMTO)81